The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_000180.4(GUCY2D):c.61T>C (p.Trp21Arg)

CA145844

92581 (ClinVar)

Gene: GUCY2D
Condition: GUCY2D-related recessive retinopathy
Inheritance Mode: Autosomal recessive inheritance
UUID: e87d9cbf-31c0-4658-8610-7a5c1b598ce2
Approved on: 2025-01-30
Published on: 2025-01-30

HGVS expressions

NM_000180.4:c.61T>C
NM_000180.4(GUCY2D):c.61T>C (p.Trp21Arg)
NC_000017.11:g.8003108T>C
CM000679.2:g.8003108T>C
NC_000017.10:g.7906426T>C
CM000679.1:g.7906426T>C
NC_000017.9:g.7847151T>C
NG_009092.1:g.5439T>C
ENST00000254854.5:c.61T>C
ENST00000254854.4:c.61T>C
NM_000180.3:c.61T>C
More

Benign

Met criteria codes 3
BP4 BA1 BS2
Not Met criteria codes 1
BS3

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for GUCY2D Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP
The NM_000180.4(GUCY2D):c.61T>C (p.Trp21Arg) variant is a missense variant predicted to replace the tryptophan at position p.21 with arginine. This variant is present in gnomAD v4.1.0 at a GrpMax allele frequency of 0.2550, with 18,276 alleles / 70,794 total alleles in the African/African American population, which is higher than the ClinGen LCA/eoRD VCEP BA1 threshold of >0.016 (BA1). This variant has been found in the homozygous state in 3,593 adult individuals in gnomAD v4.1.0, which exceeds the LCA/eoRD VCEP threshold of ≥6 (gnomAD version 4.1.0; BS2). The computational predictor REVEL gives a score of 0.141, which is below the ClinGen LCA/eoRD VCEP threshold of ≤0.183 and predicts a non-damaging effect on RetGC-1 protein function. In addition, the splicing impact predictor SpliceAI gives a delta score of 0.01 for acceptor gain, which is below the ClinGen LCA/eoRD VCEP recommended threshold of <0.1 and does not predict an impact on splicing (BP4_Moderate). The variant exhibited ~100% enzymatic activity in a guanylate cyclase assay relative to the wild-type control, which is higher than the ClinGen LCA/eoRD VCEP BS3_Supporting threshold of >50% activity, indicating that it does not trigger a severe defect in protein function, however, it lies in the signal peptide and may be considered ineligible for PS3 or BS3 due to incompatibility with in vitro activity assays (PMID: 11328726, Figure 1). In summary, this variant meets the criteria to be classified as benign for GUCY2D-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: BA1, BS2, and BP4_Moderate. (VCEP specifications version 1.0.0; date of approval 01/22/2025).
Met criteria codes
BP4
The computational predictor REVEL gives a score of 0.141, which is below the ClinGen LCA / eoRD VCEP threshold of ≤0.183 and predicts a non-damaging effect on RETGC-1 function. In addition, the splicing impact predictor SpliceAI gives a delta score of 0.01 for acceptor gain, which is below the ClinGen LCA / eoRD VCEP recommended threshold of <0.1 and does not predict an impact on splicing (BP4_Moderate).
BA1
This variant is present in gnomAD v.4.1.0 at a GrpMax allele frequency of 0.2550, with 18,276 alleles / 70,794 total alleles in the African / African American population, which is higher than the ClinGen LCA / eoRD VCEP BA1 threshold of >0.016 (BA1).
BS2
This variant has been found in the homozygous state in 3,593 adult individuals in gnomAD v.4.1.0, which exceeds the LCA/eoRD VCEP threshold of ≥6 (gnomAD version 4.1.0; BS2)
Not Met criteria codes
BS3
The variant exhibited ~100% enzymatic activity in a guanylate cyclase assay relative to the wild-type control, which is higher than the ClinGen LCA / eoRD VCEP BS3_Supporting threshold of >50% activity, indicating that it does not trigger a severe defect in protein function, however, it lies in the signal peptide and may be considered ineligible for PS3 or BS3 due to incompatibility with in vitro activity assays (PMID: 11328726, Figure 1).
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.